Ocular Therapeutix
Develops hydrogel-delivered retinal therapies and commercial ophthalmic drug inserts.
$10.45
After-hours close+0.09 (+0.87%)
At close$10.36(−4.25%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 96.16%210.56M sharesInsiders 2.87%6.29M sharesOther 0.97%2.11M shares
Shares outstanding 218.96M · Float 184.90M · 84.5% free float
Institutions13F, as of Jun 30, 2026
276 holders · 210.56M shares · 36 new positions · 142 increased · 78 reduced · 44 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 32.84M | 15.00% | +190.3K | Aug 13, 2026 |
| Deep Track Capital, LP | 19.69M | 8.99% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 19.38M | 8.85% | +3.24M | Aug 7, 2026 |
| Avoro Capital Advisors LLC | 12.54M | 5.73% | +225.0K | Aug 14, 2026 |
| Summer Road LLC | 12.21M | 5.58% | +328.5K | Aug 10, 2026 |
| VR Adviser, LLC | 10.35M | 4.73% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 8.83M | 4.03% | +113.6K | Aug 13, 2026 |
| Price T Rowe Associates Inc /MD/ | 7.62M | 3.48% | +1.73M | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 15.00% | 31.79M | 13G | Nov 5, 2025 ↗ |
| Deep Track Capital, LP | 9.53% | 20.85M | 13G | May 15, 2026 ↗ |
| Avoro Capital Advisors LLCincl. Behzad Aghazadeh | 7.90% | 12.71M | 13G | Nov 14, 2024 ↗ |
| BlackRock, Inc. | 5.80% | 10.17M | 13G | Oct 17, 2025 ↗ |
| Summer Road LLC | 5.70% | 12.13M | 13G | Dec 8, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Pravin Dugel | director, officer: See Remarks | 3.27M | 1.49% | Aug 26, 2026 |
| Donald Notman | officer: Chief Operating Officer | 366.4K | 0.17% | Feb 17, 2026 |
| Sanjay Nayak | officer: Chief Strategy Officer | 326.9K | 0.15% | Aug 26, 2026 |
| Jeffrey S. Heier | officer: Chief Scientific Officer | 318.3K | 0.15% | Aug 26, 2026 |
| Nadia Waheed | officer: Chief Medical Officer | 300.1K | 0.14% | Jun 5, 2026 |
| Peter Kaiser | officer: Chief Development Officer | 264.4K | 0.12% | Aug 26, 2026 |
| Richard L. Md Lindstrom | director | 260.9K | 0.12% | Jun 12, 2026 |
| Namrata Saroj | officer: Chief Business Officer | 254.6K | 0.12% | Jan 6, 2026 |
| Steve Lawrence Meyers | officer: Chief Commercial Officer | 217.6K | 0.10% | Jan 6, 2026 |
| Todd Anderman | officer: Chief Legal Officer | 152.5K | 0.07% | Jan 6, 2026 |
6 ten-percent owners hold 13.85M shares by Form 4, outside the officers-and-directors figure above · 11 people have not refiled in the last 18 months (2.78M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 24, 2026 | Jeffrey S. Heierofficer: Chief Scientific Officer | Sale | 3,296 | $10.78 | 318,326 |
| Aug 24, 2026 | Sanjay Nayakofficer: Chief Strategy Officer | Sale | 1,897 | $10.78 | 326,898 |
| Aug 24, 2026 | Peter Kaiserofficer: Chief Development Officer | Sale | 3,035 | $10.77 | 264,378 |
| Aug 24, 2026 | Pravin Dugeldirector, officer: See Remarks | Sale | 21,649 | $10.77 | 2,525,429 |
| Jun 3, 2026 | Nadia Waheedofficer: Chief Medical Officer | Sale | 14,828 | $8.27 | 300,079 |
| May 26, 2026 | Sanjay Nayakofficer: Chief Strategy Officer | Sale | 1,858 | $8.20 | 328,795 |
| May 26, 2026 | Jeffrey S. Heierofficer: Chief Scientific Officer | Sale | 3,018 | $8.20 | 320,350 |
| May 26, 2026 | Peter Kaiserofficer: Chief Development Officer | Sale | 2,967 | $8.20 | 266,141 |
| May 26, 2026 | Pravin Dugeldirector, officer: See Remarks | Sale | 21,156 | $8.20 | 2,597,170 |
| Feb 23, 2026 | Sanjay Nayakofficer: Chief Strategy Officer | Sale | 1,759 | $8.28 | 330,653 |
CongressHouse and Senate disclosures
Not reported.